2005
DOI: 10.1016/j.bbrc.2005.05.132
|View full text |Cite
|
Sign up to set email alerts
|

Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

2
596
0
16

Year Published

2006
2006
2021
2021

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 879 publications
(614 citation statements)
references
References 73 publications
2
596
0
16
Order By: Relevance
“…VEGF/VEGF receptor pathway represents a key player in tumor-induced angiogenesis and, consequently, tumor progression and metastasis. The humanized anti-VEGF monoclonal antibody bevacizumab has been recently approved for cancer treatment and results are encouraging even if not untroubled (23,24). Endocannabinoids warrant further investigation since they have been clearly shown to interfere with the VEGF pathway in different systems and may provide a useful tool to target VEGF in cancer.…”
Section: Discussionmentioning
confidence: 99%
“…VEGF/VEGF receptor pathway represents a key player in tumor-induced angiogenesis and, consequently, tumor progression and metastasis. The humanized anti-VEGF monoclonal antibody bevacizumab has been recently approved for cancer treatment and results are encouraging even if not untroubled (23,24). Endocannabinoids warrant further investigation since they have been clearly shown to interfere with the VEGF pathway in different systems and may provide a useful tool to target VEGF in cancer.…”
Section: Discussionmentioning
confidence: 99%
“…147,148 For instance, the antibody bevacizumab (Avastin) targets VEGF-A to inhibit angiogenesis in metastatic cancers. 149 In addition, soluble decoy receptors can act as "VEGF-Traps" to suppress tumor growth and vascularization. 150 Kinase blockers, including sunitinib malate (Sutent), can directly target Vegfr2 to inhibit its kinase activity.…”
Section: Src and Downstream Chemotherapeutic Targetsmentioning
confidence: 99%
“…Bevacizumab O Bevacizumab (Avastin ® ; Genentech, Inc, San Francisco, Califórnia, USA) é um anticorpo monoclonal humanizado contra todas as isoformas de VEGF (37)(38) . Esta substância foi desenvolvida e recebeu aprovação do FDA (fevereiro, 2004) para ser utilizada por via intravenosa no tratamento do câncer cólon-retal metastático (39) .…”
Section: Agentes Antivegfunclassified